Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia

By D. Rolnik, D. Wright, L. Poon, N. O’Gorman, A. Syngelaki, C. de Paco Matallana, R. Akolekar, S. Cicero, D. Janga, Mandeep Singh and 10 more. New England Journal of Medicine, 2017

1,839 citations recorded by the source corpus.

Subfields: Obstetrics and Gynecology

View Paper: https://www.semanticscholar.org/paper/526205a9f834ef4ab04fbe0f992e15bc51df6dd0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. L. Magee
2. M. Brown
3. D. Hall
4. S. Gupte
5. Mark A. Brown
6. Jimmy Espinoza
7. A. Hennessy
8. S. Karumanchi

Citations in the corpus

• The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice. (2021, background): “Identifying women in this way, and giving them low-dose aspirin, reduces the incidence of preterm (but not term) pre-eclampsia [91].”
• Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin Summary, Number 222. (2020, methodology): “domized trial performed by the same research group (89).”
• The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for international practice. (2018, background): “37  An important finding in the ASPRE trial (37) was confirmation that aspirin at a dose of 150mg at night conferred no greater risk to pregnant women (or their newborns) than placebo.”
• Hypertensive Disorders of Pregnancy: ISSHP Classification, Diagnosis, and Management Recommendations for International Practice. (2018, background): “No first or second trimester test or set of tests can reliably predict the development of all cases of preeclampsia; however, a combination of maternal risk factors, BP, PlGF, and uterine artery Doppler can select women who may benefit in particular from 150 mg/d of aspirin to prevent preterm but no”